OTC - ACTIVE INGREDIENT SECTION
glycerin
glycerin
wter butylene glycol, caffeine etc
a complete regimen for restorative body shape
keep out of reach of the children
Apply suitable amount of the formula to each are of the body hich can include arms, thighs, stomach and/or buttocks and vigorously massage VELA SHAPE RESCULPTING GEL over the targeted areas in a circular motion until full absorption occurs.
Exertise activity is strongly recommended after the use of the VElA SHAPE RESCULPTING GEL
1. If the following symptoms occur after product use, stop using the product immediately and consult a dermatologist (continuous use can exacerbate the symptoms).
1) Occurrence of red spots, swelling, itchiness, and other skin irritation
2) If the symptoms above occur after the application area is exposed to direct sunlight
2. Do not use on open wounds, eczema, and other skin irritations
3. Precaution for Storage and Handling
1) Close the lid after use
2) Keep out of reach of infants and children
3) Do not to store in a place with high/low temperature and exposed to direct sunlight
4. Use as avoiding eye areas.
for external use only
| Class | Version | Type | Effective |
|---|---|---|---|
| GLYCERIN Pharmacologic Class Indexing | 2 | Indexing - Pharmacologic Class | 20180813 |
| Product concept | Relation | Version | Effective |
|---|---|---|---|
| 7dea7767-9f52-b60a-5435-33cb9cc28bae | Product name | 4 | 20250124 |
| 6338270f-96cb-0ecb-6fbb-0a9bc78001f4 | Product name | 7 | 20250116 |
| 0ca83774-3f79-b837-5d6f-c210102f3bc8 | Product name | 6 | 20250114 |
| 41b814f3-0166-1c53-c9ef-a0794c7daf9d | Product name | 3 | 20221110 |
| a590be26-846c-8659-a5a1-fb25907965dc | Product name | 2 | 20221110 |
| 2dc76302-91c0-4c35-ad78-99adfb049c4b | Product name | 1 | 20200603 |
| e6065d4b-5ae1-476f-a40e-f2851cbb5d2b | Product name | 2 | 20180221 |
| f212291f-05fe-9603-fc7e-bd73e38ce1e6 | Product name | 2 | 20161129 |
| 182f9ab4-4ab5-c449-200f-87ce2ce8e550 | Product name | 2 | 20151105 |
| 332e86c3-7875-ca6e-f934-2206d2b31996 | Product name | 1 | 20140508 |
| 56625fcc-aa34-9d30-d0e9-1c1beb37ea21 | Product name | 1 | 20140508 |
| 7dfac40f-a405-cd2e-7c06-3059ec0e1092 | Product name | 1 | 20140508 |
| 96c2be53-8e44-452d-56a2-d255b2f1af2d | Product name | 1 | 20140508 |
| bf8bd5f7-495f-4022-2780-7ded7ea7ea44 | Product name | 1 | 20140508 |
| d223c173-c39b-d764-47d4-d671d3088815 | Product name | 1 | 20140508 |
| e01133ad-4dcd-c7f3-454b-2ff569ee160a | Product name | 1 | 20140508 |
| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 71588-0007-1 | 2020-01-31 | C162847 | 48780-1 | 9d75b9d0-e470-f424-e053-dadaa90a57ce | Drug Facts |
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 71588-0007-1 | Vela Shape Resculpting Body firming toning tightening | 150 mL in 1 TUBE | GEL | 150 | 1 |
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 71588-0007 | VELA SHAPE RESCULPTING BODY FIRMING TONING TIGHTENING (GLYCERIN) GEL [EZEKIELCOSMETIC CO., LTD] | 1 | Legacy NDC, 1 package rows | 20170818_57000702-2687-5a22-e054-00144ff8d46c.zip |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 71588-0007 | 71588-0007-1 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| WATER | 059QF0KO0R | IACT |
| CAFFEINE | 3G6A5W338E | IACT |
| BUTYLENE GLYCOL | 3XUS85K0RA | IACT |
| GLYCERIN | PDC6A3C0OX | ACTIB |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| 57000702-2688-5a22-e054-00144ff8d46c | 57000702-2687-5a22-e054-00144ff8d46c | 2017-08-17 | Warnings | 57000702-2688-5a22-e054-00144ff8d46c 57000702-2687-5a22-e054-00144ff8d46c |
Adverse event summaries are temporarily unavailable. Other product information remains available.